|
| Status |
Public on Jul 14, 2015 |
| Title |
NCI-H526, DMSO for 7 days, rep 2 |
| Sample type |
RNA |
| |
|
| Source name |
NCI-H526 cells treated with DMSO for 7 days
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: NCI-H526
passages: multiple
treatment: DMSO for 7 days
|
| Treatment protocol |
DMSO or 1uM GSK2879552
|
| Growth protocol |
RPMI, 10% FBS
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was extracted, labeled according to standard Affymetrix procedures and hybridized on GeneChip HGU133 Plus 2.0 slides
|
| Label |
biotin
|
| Label protocol |
standard Affymetrix protocol
|
| |
|
| Hybridization protocol |
standard Affymetrix protocol
|
| Scan protocol |
standard Affymetrix protocol
|
| Description |
Gene expression from NCI-H526 cells treated with DMSO for 7 days
|
| Data processing |
microarray data was processed, normalized, and analyzed using the R Bioconductor package.
|
| |
|
| Submission date |
Feb 25, 2015 |
| Last update date |
Jul 14, 2015 |
| Contact name |
David Soong |
| Organization name |
GlaxoSmithKline
|
| Street address |
1250 S Collegeville Rd
|
| City |
Collegeville |
| State/province |
PA |
| ZIP/Postal code |
19426 |
| Country |
USA |
| |
|
| Platform ID |
GPL570 |
| Series (2) |
| GSE66294 |
A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibitors in SCLC (microarray) |
| GSE66298 |
A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibitors in SCLC |
|
